fadrozole has been researched along with Disease Exacerbation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T | 1 |
| Ali, SM; Brown-Shimer, S; Carney, W; Demers, L; Evans, DB; Hamer, P; Leitzel, K; Lipton, A; Pierce, K | 1 |
| Demers, L; Grossberg, H; Leitzel, K; Lipton, A; Teramoto, Y; Volas, GH | 1 |
3 trial(s) available for fadrozole and Disease Exacerbation
| Article | Year |
|---|---|
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate; Triazoles | 2003 |
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Humans; Megestrol Acetate; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate; Tissue Inhibitor of Metalloproteinase-1 | 2007 |
Serial serum c-erbB-2 levels in patients with breast carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Fadrozole; Female; Humans; Megestrol; Megestrol Acetate; Placebos; Prognosis; Receptor, ErbB-2; Remission Induction; Treatment Outcome | 1996 |